Company Filing History:
Years Active: 2019-2025
Title: Matthias Hoch: Innovator in Selective S1P1 Receptor Agonists
Introduction
Matthias Hoch is a notable inventor based in Harston, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective S1P1 receptor agonists. With a total of four patents to his name, Hoch's work is recognized for its potential impact on therapeutic regimens.
Latest Patents
Hoch's latest patents include innovative dosing regimens for selective S1P1 receptor agonists. The first patent details a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one. The second patent also focuses on a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one. These inventions aim to enhance the efficacy and safety of treatments involving S1P1 receptor modulation.
Career Highlights
Throughout his career, Matthias Hoch has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Actelion Pharmaceuticals Ltd and Vanda Pharmaceuticals Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Hoch has collaborated with esteemed colleagues in the field, including Jasper Dingemanse and Andreas Krause. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in pharmaceutical research.
Conclusion
Matthias Hoch is a distinguished inventor whose work in selective S1P1 receptor agonists has the potential to transform therapeutic approaches. His patents and collaborations reflect a commitment to innovation in the pharmaceutical industry.